Parmax Pharma AGM passes all 6 resolutions with 99.99% approval
- All six resolutions at Parmax Pharma's 32nd AGM on September 29, 2026 were passed with 99.99% votes in favour
- A total of 3,996,746 votes were polled, representing 58.10% of 6,878,886 outstanding shares eligible to vote
- Resolutions covered adoption of FY26 audited standalone financial statements and four director appointments, including Dhiren Chandulal Shah as Non-Executive Director and Chairman
- Umang Gosalia (DIN: 05153830) was re-appointed as Managing Director liable to retire by rotation
- One invalid vote (0.01%) was recorded from the Public Non-Institutions category for each resolution; no votes were cast against any resolution
*this image is generated using AI for illustrative purposes only.
Parmax Pharma Limited concluded its 32nd Annual General Meeting on September 29, 2026, with all six resolutions passed by shareholders via remote e-voting, each securing 99.99% votes in favour out of 3,996,746 valid votes polled.
The meeting, held via video conferencing, commenced at 3:30 pm and concluded at 3:52 pm. The deemed venue was the company's registered office in Rajkot, Gujarat. As on the cut-off date of September 22, 2026, the total number of shareholders on record stood at 2,151, with 6 promoter and promoter group members and 19 public shareholders attending through video conferencing. Remote e-voting was open from September 26, 2026 at 9:00 am to September 28, 2026 at 5:00 pm, facilitated by Purva Sharegistry (India) Private Limited.
Key resolutions passed
Shareholders voted on six ordinary resolutions covering governance, financial adoption, and leadership appointments. The table below summarises the outcome of each resolution.
| Resolution | Subject | Votes in favour | % in favour | Status |
|---|---|---|---|---|
| 1 | Adoption of audited standalone financial statements FY26 | 3,996,746 | 99.99 | Passed |
| 2 | Re-appointment of Umang Gosalia (DIN: 05153830) as Director | 3,996,746 | 99.99 | Passed |
| 3 | Appointment of Dhiren Chandulal Shah (DIN: 00255333) as Non-Executive Director and Chairman | 3,996,746 | 99.99 | Passed |
| 4 | Appointment of Sunil Chinubhai Shah (DIN: 11888388) as Non-Executive Director | 3,996,746 | 99.99 | Passed |
| 5 | Appointment of Anjana Paresh Shah (DIN: 00845784) as Independent Director | 3,996,746 | 99.99 | Passed |
| 6 | Appointment of Ashish Atmaram Shah (DIN: 06873593) as Non-Executive Independent Director | 3,996,746 | 99.99 | Passed |
The auditors reported no observations in their report on the financial statements for FY26, indicating a clean audit opinion for the period.
Voting participation breakdown
The total shares eligible to vote as on the cut-off date were 6,878,886. Of these, 3,996,746 votes were polled, representing 58.10% of outstanding shares. The breakdown across shareholder categories was identical for all six resolutions, as detailed below.
| Category | Shares held | Votes polled | % of outstanding shares | Votes in favour | Votes against |
|---|---|---|---|---|---|
| Promoter and Promoter Group | 4,447,794 | 3,878,979 | 87.2113 | 3,878,979 | 0 |
| Public Institutions | 0 | 0 | 0 | 0 | 0 |
| Public Non-Institutions | 2,431,092 | 117,767 | 4.8442 | 117,767 | 0 |
| Total | 6,878,886 | 3,996,746 | 58.1016 | 3,996,746 | 0 |
For each resolution, one invalid vote was recorded from the Public Non-Institutions category, accounting for 0.01% of total votes cast. No invalid votes were recorded from the Promoter and Promoter Group or Public Institutions categories. No votes were cast through poll during the live meeting for any resolution.
Governance and scrutinizer details
The meeting was attended by board members including Non-Executive Directors Dhiren Chandulal Shah, Sunil Chinubhai Shah, and Pradeep Gosalia. Nikhil Uchat, serving as Independent Director and Chairman of both the Audit Committee and Nomination and Remuneration Committee, was also present. Samsad Alam Khan, Practicing Company Secretary (FCS No. 13629, CP No. 13972), was appointed as Scrutinizer by the Board on August 14, 2026, and issued the scrutinizer's report on October 1, 2026 from Ahmedabad.
Regulatory compliance
The AGM was conducted in compliance with the Companies Act, 2013, Secretarial Standards-2, and applicable MCA and SEBI circulars on virtual meetings. The voting results and scrutinizer's report were disclosed to BSE Limited under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Results are also available on the company's website at www.parmaxpharma.com and on Purva Sharegistry's website at www.purvashare.com . Statutory registers were available for inspection throughout the meeting.
How will the appointment of Dhiren Chandulal Shah as Chairman influence Parmax Pharma's strategic direction and governance standards in the coming fiscal year?
Given the 99.99% approval rate and minimal public institutional participation, what steps might the company take to enhance retail investor engagement and broaden its shareholder base?
What specific operational or expansion plans are expected to be announced following the adoption of the clean FY26 audited financial statements?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
